PDL BioPharma sets sights on new acquisition
PDL BioPharma, Inc., of Incline Village, has submitted a proposal to acquire Neos Therapeutics, Inc., for $10.25 per share.
PDL, a company that acquires and manages a portfolio of companies, products royalties and debt in the biotech, pharmaceutical and medical device industries, sees the acquisition as a logical step in its strategic plan that would create an attractive pediatric platform and foundation for future growth.
Neos, headquartered in Grand Prairie, Texas, develops, manufactures, and commercializes extended-release products by utilizing technology platforms.
PLD first approached Neos in June.
The PDL proposal will remain outstanding for a period of 14 days. The proposal does not create any binding obligation on Neos, PDL or any of their respective affiliates.
“We are proud to be affiliated with the best of the best,” said Nancy Fennell, CEO of Dickson Realty.